AI Article Synopsis

  • Anecdotal evidence in March 2020 indicated that sudden loss of smell (hyposmia) and taste (hypogeusia) were significant symptoms of COVID-19, prompting a study on their prevalence among various patient groups.
  • In a survey conducted in Paris, they found that 33% of all COVID-19 patients reported these symptoms, but they were less common in hospitalized patients compared to those seen in outpatient settings.
  • Younger patients with these symptoms tended to experience milder respiratory issues, suggesting that olfactory and gustatory dysfunction could help identify potential COVID-19 cases, especially among younger individuals.

Article Abstract

Anecdotal evidence rapidly accumulated during March 2020 from sites around the world that sudden hyposmia and hypogeusia are significant symptoms associated with the SARS-CoV-2 pandemic. Our objective was to describe the prevalence of hyposmia and hypogeusia and compare it in hospitalized and non-hospitalized COVID-19 patients to evaluate an association of these symptoms with disease severity. We performed a cross-sectional survey during 5 consecutive days in March 2020, within a tertiary referral center, associated outpatient clinic, and two primary care outpatient facilities in Paris. All SARS-CoV-2-positive patients hospitalized during the study period and able to be interviewed (n = 198), hospital outpatients seen during the previous month (n = 129), and all COVID-19-highly suspect patients in two primary health centers (n = 63) were included. Hospitalized patients were significantly more often male (64 vs 40%) and older (66 vs 43 years old in median) and had significantly more comorbidities than outpatients. Hyposmia and hypogeusia were reported by 33% of patients and occurred significantly less frequently in hospitalized patients (12% and 13%, respectively) than in the health centers' outpatients (33% and 43%, respectively) and in the hospital outpatients (65% and 60%, respectively). Hyposmia and hypogeusia appeared more frequently after other COVID-19 symptoms. Patients with hyposmia and/or hypogeusia were significantly younger and had significantly less respiratory severity criteria than patients without these symptoms. Olfactory and gustatory dysfunction occurs frequently in COVID-19, especially in young, non-severe patients. These symptoms might be a useful tool for initial diagnostic work-up in patients with suspected COVID-19.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543958PMC
http://dx.doi.org/10.1007/s10096-020-04056-7DOI Listing

Publication Analysis

Top Keywords

hyposmia hypogeusia
20
hospitalized patients
12
patients
11
prevalence hyposmia
8
march 2020
8
hospital outpatients
8
frequently covid-19
8
patients symptoms
8
hypogeusia
6
covid-19
5

Similar Publications

The COVID-19 pandemic has caused substantial worldwide disruptions in health, economy, and society, manifesting symptoms such as loss of smell (anosmia) and loss of taste (ageusia), that can result in prolonged sensory impairment. Establishing the host genetic etiology of anosmia and ageusia in COVID-19 will aid in the overall understanding of the sensorineural aspect of the disease and contribute to possible treatments or cures. By using human genome sequencing data from the University of Iowa (UI) COVID-19 cohort (N=187) and the National Institute of Health All of Us (AoU) Research Program COVID-19 cohort (N=947), we investigated the genetics of anosmia and/or ageusia by employing feature selection techniques to construct a novel variant and gene prioritization pipeline, utilizing machine learning methods for the classification of patients.

View Article and Find Full Text PDF
Article Synopsis
  • * In our study of 71 long COVID patients, 34 experienced loss of smell and taste, with 88.2% having reduced smell (hyposmia) and 23.5% reduced taste (hypogeusia) initially.
  • * After 10 months, most patients reported improvements in their sense of smell, although significant deficits persisted for many.
View Article and Find Full Text PDF

Background: SARS-CoV-2 variants have distinct features of transmissibility, infectivity, and aggressiveness that may cause different clinical manifestations. A better understanding of the disease presentation and progression could help to outline more precise preventive and treatment frameworks. This study describes the differences in COVID-19 presentation and outcomes across five variant waves.

View Article and Find Full Text PDF

Acute Epstein-Barr Virus and SARS-CoV-2 Coinfection: A Case Report.

Curr Health Sci J

September 2024

Postgraduate Program in Dentistry, Universidade do Grande Rio (UNIGRANRIO), Rio de Janeiro, Brazil.

Article Synopsis
  • An 18-year-old female was misdiagnosed with bacterial tonsillitis and treated with antibiotics, but subsequent tests revealed she had a coinfection of Epstein-Barr Virus (EBV) and SARS-CoV-2 (COVID-19).
  • Symptoms included throat pain, cough, and enlarged lymph nodes, while tests indicated active EBV infection and confirmed COVID-19.
  • This case highlights the challenge of diagnosing coinfections and the critical role of proper lab testing to avoid incorrect treatments that could worsen the patient's health.
View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic has presented major health challenges, particularly with the emergence of new SARS-CoV-2 variants throughout multiple waves of infection.
  • A study conducted in southern Bahia, Brazil, analyzed samples from two waves in late 2021 and 2022, revealing a significant increase in positivity rates and a shift from the Delta variant in 2021 to the Omicron variant in 2022.
  • Differences in clinical symptoms were noted, with anosmia/ageusia being common in 2021 but less frequent in 2022, and other symptoms like fever and cough being more prevalent in Omicron infections compared to Delta.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!